Dual Time-Point [18F]Florbetaben PET Delivers Dual Biomarker Information in Mild Cognitive Impairment and Alzheimer's Disease
Dual Time-Point [18F]Florbetaben PET Delivers Dual Biomarker Information in Mild Cognitive Impairment and Alzheimer's Disease
复制标题
DOI：
10.3233/jad-180522
复制
发表时间：
2018-01-01
影响因子：
4
通讯作者：
Barthel, Henryk
中科院分区：
文献类型：
--
作者：
Florek, Lisa;Tiepolt, Solveig;Barthel, Henryk
背景：目前阿尔茨海默病（AD）和 AD 引起的轻度认知障碍（MCI）的研究诊断标准包括补充临床测试的生物标志物。最近，我们证明双时间点 [F-18]FBB PET 能够提供血流和淀粉样蛋白-β (A beta) 负荷替代物。目的：本研究的目的是调查这些替代物是否可以用作 AD 生物标志物。方法：112 名受试者（41 名患有 MCI，50 名可能/可能患有 AD，21 名患有其他痴呆症）接受了双时间点[F-18]FBB PET。对数据进行视觉和相对定量分析（早期 PET 数据的 Herholz 评分和晚期 PET 数据的综合 SUVR 评分）。结果：在早期图像中，42%/27%/33% 的可能/可能 AD/MCl/其他痴呆病例中存在 AD 典型模式。在晚期[F-18]FBB PET中，42%/29%/38%的可能/可能的AD/MCI/其他痴呆病例是Aβ阳性。 17% 的 MCI 被归类为“高可能性 AD 引起的 MCI”，44% 的可能 AD 被归类为“可能的 AD，具有 AD 病理生理过程的高度证据”，28% 的可能 AD 被归类为“可能的 AD，具有 AD 病理生理过程的证据”。 27% 的受试者显示出阳性诊断和进展生物标志物。可能/可能 AD 与 MCI 相比，Herholz 评分较低（0.85 +/- 0.05 与 0.88 +/- 0.04，p = 0.015）。 A β 阳性患者与 A β 阴性患者相比，复合晚期 SUVR 显着更高（1.65 +/- 0.23 对比 1.15 +/- 0.17，p < 0.005）。 Herholz 和 MMSE 评分呈正相关 (R = 0.30 p = 0.006)。结论：双时间点 [F-18]FBB PET 提供双重生物标志物信息，能够根据既定的诊断标准对 MCI 和 AD 痴呆患者进行分类。因此，双时间点 [F-18]FBB PET 具有补充诊断性痴呆检查的巨大潜力。
Background: Current research diagnostic criteria for Alzheimer's disease (AD) and mild cognitive impairment (MCI) due to AD include biomarkers to supplement clinical testing. Recently, we demonstrated that dual time-point [F-18]FBB PET is able to deliver both blood flow and amyloid-beta (A beta) load surrogates.Objective: The aim of this study was to investigate whether these surrogates can be utilized as AD biomarkers.Methods: 112 subjects (41 with MCI, 50 with probable/possible AD, 21 with other dementias) underwent dual time-point [F-18]FBB PET. Data were visually and relative quantitatively (Herholz scores for the early and composite SUVRs for the late PET data) analyzed.Results: In the early images AD-typical patterns were present in 42%/27%/33% of probable/possible AD/MCl/other dementia cases. In late [F-18]FBB PET, 42%/29%/38% of probable/possible AD/ MCl/other dementia cases were A beta-positive. 17% of the MCIs were categorized as "MCI due to AD-high likelihood", 44% of the probable ADs as "probable AD with high evidence of AD pathophysiological process" and 28% of the possible ADs as "possible AD with evidence of AD pathophysiological process". 27% of all subjects showed a positive diagnostic and progression biomarker. Herholz scores were lower (0.85 +/- 0.05 versus 0.88 +/- 0.04, p = 0.015) for probable/possible AD versus MCI. Composite late phase SUVRs were significantly higher (1.65 +/- 0.23 versus 1.15 +/- 0.17, p < 0.005) in A beta-positive versus A beta-negative patients. Herholz and MMSE scores were positively correlated (R = 0.30 p = 0.006).Conclusion: Dual time-point [F-18]FBB PET provides dual biomarker information which enables to categorize MCI and AD dementia patients according to established diagnostic criteria. Thus, dual time-point [F-18]FBB PET has great potential to supplement diagnostic dementia workups.